Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 7, 2006; 12(9): 1336-1345
Published online Mar 7, 2006. doi: 10.3748/wjg.v12.i9.1336
Published online Mar 7, 2006. doi: 10.3748/wjg.v12.i9.1336
Generic name | Brand name | PhCob | Esophagus | Stomach | Colorectum | ||||||||
Cancer cell line | CIAc | reflux-induced animal | Human (BEd) | Cancer cell line | CIAc | MIAe | Cancer cell line | CIAc | MIAe | Human (FAPf) | |||
Tricyclic | |||||||||||||
Celecoxib | Celebrex | Pfizer | (23) | (46,47) | (75) | (76,77) | (81,82) | (54) | (56) | ||||
MF-tricyclic | ECa | Merck | (21) | (53,87) | |||||||||
Rofecoxib | Vioxx | Merck | (24) | (55) | |||||||||
Tilmacoxib | Japan Tobacco | (20) | (78) | (88,89) | |||||||||
Valdecoxib Bextra | Pfizer | ||||||||||||
EtoricoxibArcoxia | Merck | ||||||||||||
Methanesulphonamide | |||||||||||||
NS-398 | ECa | Taisho | (18,19,70,71) | (44,45,72) | (49) | (72) | (83) | ||||||
Nimesulide | Mesulid | Helsinn | (73) | (48) | (84) | (90) | |||||||
Flosulide | Schering | (70) | |||||||||||
Others | |||||||||||||
Nabumetone | Relafen | Glaxo Smith Kline | (85) | (91) | |||||||||
Meloxicam | Mobic | Boehringer Ingelheim | (79,80) | (86) | |||||||||
Etodolac | Lodine | Wyeth | (74) | (74) | |||||||||
Lumiracoxib | Prexige | Novartis |
Drug | Outcomes | Reference | |||||
Name | Concentration | Term | Animal model | Inhibition rate (%) | P value | Reporter (#) | Year |
carcinogen-induced rat model | |||||||
Celecoxib | 1500 ppm | 5-16 wk | F344 rat, AOMa | 40 (ACF) | P < 0.001 | Reddy et al (92) | 1996 |
NS-398 | 1 mg/kg•bw | 5-11 wk | F344 rat, AOMa | 34 (ACF) | P < 0.05 | Yoshimi et al (83) | 1997 |
10 mg/kg•bw | 47 (ACF) | P < 0.01 | |||||
Celecoxib | 1500 ppm | 5-50 wk | F344rat, AOMa | 93(colontumor) | P<0.00001 | Kawamori et al (81) | 1998 |
Nimesulide | 200 ppm | 6-30 wk | ICRmouse,AOMa | 36(adenocarcinoma) | NS | Fukutake et al (84) | 1998 |
400 ppm | 50(adenocarcinoma) | P < 0.05 | |||||
Celecoxib | 500 ppm | 5-58 wk | F344 rat, AOMa | 55(adenocarcinoma) | P < 0.001 | Reddyet al (82) | 2000 |
1000 ppm | 5-58 wk | 62(adenocarcinoma) | P < 0.001 | ||||
1500 ppm | 5-58 wk | 77(adenocarcinoma) | P < 0.0001 | ||||
1500 ppm | 22-58 wk | 47(adenocarcinoma) | P < 0.01 | ||||
Nabumetone | 750 ppm | for18 wk | F344 rat, AOMa | 15 (ACF) | P < 0.05 | Roy et al (85) | 2001 |
1500 ppm | 37 (ACF) | P < 0.01 | |||||
Apc gene mutant mouse model | |||||||
MF-tricyclic | 3,5 mg/kg•d | 3-11 wk | ApcΔ716 | 52(intestinalpolyp) | P = 0.0037 | Oshima et al (53) | 1996 |
14 mg/kg•d | 62 (intestinal polyp) | P < 0.0001 | |||||
Nimesulide | 400 ppm | 4-15 wk | ApcΔ850 (Min) | 48 (intestinal polyp) | Nakatsugi et al (90) | 1997 | |
Celecoxib | 150 ppm | 30-80 d | ApcΔ850 (Min) | 48 (intestinal polyp) | P < 0.05 | Jacoby et al (54) | 2000 |
500 ppm | 29(intestinalpolyp) | ||||||
1500 ppm | 71(intestinalpolyp) | ||||||
JTE-522 | 0.001 (%) | 4-12 wk | ApcΔ474 | 9 (intestinal polyp) | NS | Sasai et al (88) | 2000 |
0.01 (%) | 32 (intestinal polyp) | P < 0.05 | |||||
Nabumetone | 900 ppm | 5-15 wk | ApcΔ850 (Min) | 50(smallbowelpolyp) | P < 0.05 | Roy et al (91) | 2001 |
65(largebowelpolyp) | P < 0.05 | ||||||
MF-tricyclic | 13 mg/kg/d | 3-7 wk | ApcΔ850 (Min) + | 48 (intestinal polyp) | P < 0.001 | Lal et al (87) | 2001 |
Msh2-/- | |||||||
Rofecoxib | 0.0025 (%) | 3-11 wk | ApcΔ716 | 36 (intestinal polyp) | Oshima et al (55) | 2001 | |
0.0075 (%) | 55 (intestinal polyp) | ||||||
JTE-522 | 0.01 (%) | 4-12 wk | ApcΔ474 | 49 (large adenoma) | P < 0.01 | Sunayama et al (89) | 2001 |
-28 (small adenoma) | NS |
- Citation: Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K. Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: A review and report of personal experience. World J Gastroenterol 2006; 12(9): 1336-1345
- URL: https://www.wjgnet.com/1007-9327/full/v12/i9/1336.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i9.1336